160 related articles for article (PubMed ID: 19692817)
1. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET.
Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Haberkorn U; Strauss LG
Clin Nucl Med; 2009 Sep; 34(9):576-84. PubMed ID: 19692817
[TBL] [Abstract][Full Text] [Related]
2. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study.
Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Eisenhut M; Pan L; Haberkorn U; Strauss LG
Mol Imaging Biol; 2007; 9(5):308-17. PubMed ID: 17623254
[TBL] [Abstract][Full Text] [Related]
3. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
Dimitrakopoulou-Strauss A; Strauss LG; Burger C; Rühl A; Irngartinger G; Stremmel W; Rudi J
J Nucl Med; 2004 Sep; 45(9):1480-7. PubMed ID: 15347714
[TBL] [Abstract][Full Text] [Related]
4. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.
Dimitrakopoulou-Strauss A; Strauss LG; Egerer G; Vasamiliette J; Schmitt T; Haberkorn U; Kasper B
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1481-9. PubMed ID: 20336454
[TBL] [Abstract][Full Text] [Related]
5. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study.
Dimitrakopoulou-Strauss A; Strauss LG; Egerer G; Vasamiliette J; Mechtersheimer G; Schmitt T; Lehner B; Haberkorn U; Stroebel P; Kasper B
J Nucl Med; 2010 Apr; 51(4):551-8. PubMed ID: 20351350
[TBL] [Abstract][Full Text] [Related]
6. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis.
Okazumi S; Dimitrakopoulou-Strauss A; Schwarzbach MH; Strauss LG
Hell J Nucl Med; 2009; 12(3):223-8. PubMed ID: 19936332
[TBL] [Abstract][Full Text] [Related]
7. PET-FDG as predictor of therapy response in patients with colorectal carcinoma.
Dimitrakopoulou-Strauss A; Strauss LG; Rudi J
Q J Nucl Med; 2003 Mar; 47(1):8-13. PubMed ID: 12714949
[TBL] [Abstract][Full Text] [Related]
8. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
[TBL] [Abstract][Full Text] [Related]
9. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
[TBL] [Abstract][Full Text] [Related]
11. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions.
Dimitrakopoulou-Strauss A; Strauss LG; Heichel T; Wu H; Burger C; Bernd L; Ewerbeck V
J Nucl Med; 2002 Apr; 43(4):510-8. PubMed ID: 11937595
[TBL] [Abstract][Full Text] [Related]
12. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
[TBL] [Abstract][Full Text] [Related]
13. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
14. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
15. Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection?
Strauss LG; Klippel S; Pan L; Schönleben K; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):868-77. PubMed ID: 17219134
[TBL] [Abstract][Full Text] [Related]
16. PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.
Zamagni E; Nanni C; Mancuso K; Tacchetti P; Pezzi A; Pantani L; Zannetti B; Rambaldi I; Brioli A; Rocchi S; Terragna C; Martello M; Marzocchi G; Borsi E; Rizzello I; Fanti S; Cavo M
Clin Cancer Res; 2015 Oct; 21(19):4384-90. PubMed ID: 26078390
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of [
Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
[TBL] [Abstract][Full Text] [Related]
19. An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline.
Sarocchi M; Bauckneht M; Arboscello E; Capitanio S; Marini C; Morbelli S; Miglino M; Congiu AG; Ghigliotti G; Balbi M; Brunelli C; Sambuceti G; Ameri P; Spallarossa P
J Transl Med; 2018 Oct; 16(1):295. PubMed ID: 30359253
[TBL] [Abstract][Full Text] [Related]
20. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
